The U.S. Federal Trade Commission reached a proposed settlement with CVS Caremark, one of the largest pharmacy benefit managers in the U.S., over allegations the company artificially inflated the price of insulin and impeded access to the lifesaving diabetes treatment, STAT notes, citing a document filed on the agency website. A CVS spokesperson wrote that the “proposed agreement is subject to review and approval by the FTC chair. Final terms ar…